

## Rheumatoid Arthritis: The Next Generation of Treatment

**Release date:** September 12, 2016  
**Expiration date:** September 12, 2017

### Pharmacy Credit

**Instructions for Receiving Continuing Pharmacy Education (CPE) Credit: Testing and Grading Information**

This lesson is free online; receive instant grading and request your CE credit at [www.PharmacyTimes.org](http://www.PharmacyTimes.org).

### Testing and Grading Directions

1. Each participant evaluating the activity and achieving a passing grade of 70% or higher on the online posttest is eligible to receive CE credit.

2. Participants receiving a failing grade on the exam will be notified and permitted to take 1 reexamination at no cost.

3. To receive your credit online, go to [www.PharmacyTimes.org](http://www.PharmacyTimes.org) to complete the online posttest (achieving a passing grade of 70% or better) and the online activity evaluation form before the expiration date. Your CE credit will be automatically uploaded to CPE Monitor™. Please ensure that your Pharmacy Times account is updated with your NABP e-profile ID number and your date of birth (MMDD format). Participation data will *not* be uploaded into CPE Monitor™ if you do not have your NABP e-profile ID number and date of birth entered into your profile on [www.PharmacyTimes.org](http://www.PharmacyTimes.org).

### Sample of Online Posttest

Choose the best answer for each of the following:

- Which gene complex is the most influential in rheumatoid arthritis (RA)?**
  - Human leukocyte antigen
  - Protein tyrosine phosphatase
  - Tyrosine kinase 2
  - Non-receptor type 22 PADI and peptidyl arginine deiminase
- Which of the following tumor necrosis factor (TNF) inhibitors is not a monoclonal antibody?**
  - Adalimumab
  - Infliximab
  - Golimumab
  - Etanercept
- The cornerstone of treatment for RA is which of the following?**
  - Methotrexate
  - TNF inhibitors
  - Non-TNF biologics
  - Glucocorticosteroids
- Which of the following is true regarding the intracellular Janus kinase (JAK)?**
  - JAKs are not potential inhibitory targets; however, they can help in RA.
  - JAKs do not engage with cytokines, growth factors, and hormones.
  - JAKs exert their effect primarily through activation of specific signaling proteins.
  - Signal transducers and activators of transcription cannot modulate intracellular activity, including the expression of target genes.
- Interleukin-17-producing \_\_\_\_ cells mediate 3 phases of RA: inflammation, cartilage destruction, and bone erosion.**
  - T helper (Th) 1
  - Th 13
  - Th 17
  - Th 21
- MG, a 38-year-old female, comes to the office complaining of increasing morning stiffness and pain. She has moderate to severe RA. Upon questioning, MG states that she tried methotrexate for 2 years and has been taking etanercept for the past 6 months. Her pain has not improved since starting etanercept. Her physician wants to start a JAK inhibitor. Which JAK inhibitor is FDA-approved for use in RA?**
  - Baricitinib
  - Tofacitinib
  - Upadacitinib
  - Peficitinib
- A substantial portion of the high indirect costs of RA are due to:**
  - Hospitalization
  - Poor quality of life
  - Work-related deficits
  - Pain and fatigue
- Direct medical costs of patients with RA-related comorbidities are \_\_\_\_\_ that of patients without comorbidities.**
  - The same as
  - Double
  - Triple
  - Quadruple

9. The majority of the medical costs related to RA comes from:

- A. Hospitalization
- B. Specialist visits
- C. Specialty drugs
- D. Disability payments

10. It is difficult to determine if biologics are cost-effective overall in RA because:

- A. Available studies are very heterogeneous.
- B. There are few well-designed studies.
- C. The majority of studies used quality-adjusted life-year gains of \$100,000.
- D. Most published studies focus on mild to moderate RA.

# SAMPLE POSTTEST

